福避痛被广泛用于治疗痛风和高尿酸血症,能有效控制尿酸水平并减轻相关症状。 2. 福避痛的作用机制(Mechanism of Action)福避痛属于一种非嘌呤类抑制剂,能抑制黄嘌呤氧化酶(Xanthine Oxidase)的活性,从而减少体内尿酸的产生。黄嘌呤氧化酶是一种酶,它参与嘌呤代谢过程中尿酸的生成。福避痛通过抑制该酶的活性,降低尿酸水平...
How does sunitinib work (mechanism of action)? Sunitinib is a type of medicine known as a tyrosine kinase inhibitor (TKI). It works by targeting specific receptors on cancer cells. By blocking the action of these receptors, sunitinib can cause cancer cells to die and prevent cancer cells from...
Sunitinib, a multi-targeted tyrosine kinase inhibitor, is frequently incorporated into the management of papillary thyroid carcinoma refractory to standard therapies. Although clinical trials are in progress, the mechanism of action in papillary thyroid carcinomas is not clear, especially regarding the ...
Mechanism of action Sunitinib inhibits multiple RTKs in biochemical and cell- based assays and exerts potent antiangiogenesis and antitumor effects in animal experiments. In vivo, sunitinib downregu- lates myeloid-derived suppressor cells (MDSC), which are thought to contribute to the antitumor effects...
Since it first demonstrated its efficacy ten years ago, overall survival of mRCC has more than doubled, in part due to sunitinib. In most recent years, progress has been made in the comprehension of its mechanism of action and resistance.Areas Covered: In this article, clinical trials ...
Cancer Treatment: Sunitinib Malate is primarily used in the field of oncology for the treatment of certain types of cancer. Its mechanism of action involves inhibiting the activity of specific proteins in cancer cells, thereby slowing down the growth and spread of tumors. This targeted therapy has...
The proposed mechanism behind this action is that the Akt/β-catenin pathway gets activated in response to drug-induced hypoxia and then it stimulates the growth of the distinct aggressive tumor cells.125 To overcome this problem, combination therapy of this drug with agents that can block the ...
In a recent study, we have investigated the relationship between germ-line variants in genes encoding proteins involved in sunitinib disposition, metabolism and mechanism of action and the development of common toxicities, including haematological toxicities (van Erp et al, 2009). We found a strong ...
Considering the differences in mechanism of action between these two targeted agents and recognizing that the trial had no molecular selection as entry criteria, we investigated whether first-line PFS (PFS1L) for everolimus might vary within molecularly defined patient subgroups. Specifically, we ...
8,9,10 The discovery of biomarkers that could predict patients’ response to sunitinib would improve cost-effectiveness by allowing selecting patients who are likely to respond while other patients could be directed to therapies with a different mechanism of action or for clinical trials of novel ...